<code id='1E54943972'></code><style id='1E54943972'></style>
    • <acronym id='1E54943972'></acronym>
      <center id='1E54943972'><center id='1E54943972'><tfoot id='1E54943972'></tfoot></center><abbr id='1E54943972'><dir id='1E54943972'><tfoot id='1E54943972'></tfoot><noframes id='1E54943972'>

    • <optgroup id='1E54943972'><strike id='1E54943972'><sup id='1E54943972'></sup></strike><code id='1E54943972'></code></optgroup>
        1. <b id='1E54943972'><label id='1E54943972'><select id='1E54943972'><dt id='1E54943972'><span id='1E54943972'></span></dt></select></label></b><u id='1E54943972'></u>
          <i id='1E54943972'><strike id='1E54943972'><tt id='1E54943972'><pre id='1E54943972'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:Wikipedia    Page View:35586
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In